Exact sciences corporation stock.

On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ...Shares Held % O/S Share Change Filing Date; The Vanguard Group, Inc. 17,175: 9.52: 164: 06/30/2023: JPMorgan Investment Management, Inc. 12,307: 6.82: 878: 06/30/2023Nov 14, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ... Estimate Trend. In the past 60 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has moved 25% north to $2.16. The Zacks Consensus Estimate for 2023 revenues is pegged at $2. ...Exact Sciences Corporation completed the acquisition of Omicera Diagnostics Gmbh for $19.41 million on May 2, 2022. As part of the acquisition, Exact Sciences issued 265,186 common shares, contingent consideration of $4.6 million, Working capital adjustment to be settled in cash of $0.016 million and maximum of $6 million of additional cash ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...

Exact Sciences Corporation. 21 Feb, 2023, 16:05 ET. Reports record revenue, expects revenue of $2,265 -2,315 million and positive adjusted EBITDA for full year 2023. Fourth quarter and 2022 ...As of November 29, 2023, Exact Sciences Corp had a $11.7 billion market capitalization, compared to the Biotechnology & Medical Research median of $79.5 million. Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price …

Estimate Trend. In the past 60 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has moved 25% north to $2.16. The Zacks Consensus Estimate for 2023 revenues is pegged at $2. ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...Exact Sciences Corporation. 01 Aug, 2023, 16:05 ET. Reports record results, generates positive free cash flow, raises full-year guidance. Second-quarter 2023 highlights. Total second quarter ...Sentiment. Exact Sciences (EXAS) has an AI Score of /10 (Buy) because its overall probability of beating the market (S&P 500) in the next 3 months (43.63%) is +42.63% vs. the average probability (%) of US stocks analyzed by our Artificial Intelligence. The AI-powered overall analysis of Exact Sciences (EXAS) is based on the fundamental ...Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more.

Get the latest Exact Sciences Corporation (EXAS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to ...

Buy candidate since Nov 17, 2023 Loss -1.39% PDF. The EXACT Sciences Corporation stock price gained 0.368% on the last trading day (Wednesday, 22nd Nov 2023), rising from $65.14 to $65.38. During the last trading day the stock fluctuated 3.02% from a day low at $64.84 to a day high of $66.80. The price has been going up and down for this period ...Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more.Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...Year to date, Exact Sciences has outperformed its industry. The stock has gained 57.6% against the industry's 5.3% decline. Exact Sciences exited the first quarter of 2023 with better-than ...Exact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | NasdaqMADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.

MADISON, Wis., April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after the close of the U.S. financial markets on May 9, 2023.Exact Sciences (EXAS) Stock Price & Analysis ; Previous Close$66.3 ; Volume2.13M ; Average Volume (3M)1.45M ; Market Cap. $11.99B ; Enterprise Value$13.82B.Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated ...Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...01-Nov-2023 ... MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, ...Exact Sciences Corporation (EXAS) Shares Pulled Back in Q3. Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter.

EXACT Sciences Corporation stock price live 67.03, this page displays NASDAQ EXAS stock exchange data. View the EXAS premarket stock price ahead of the market session or assess the after hours quote.

Nov 17, 2023 · Get the latest stock price, quote, news and history of Exact Sciences Corporation Common Stock (EXAS), a biotechnology company that develops and commercializes diagnostic tests for cancer and other diseases. See real-time data, market cap, key data and news of EXAS on Nasdaq. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative …The number of shares outstanding of the Registrant’s $0.01 par value Common Stock as of February 20, 2023 was178,217,142. ... EXACT SCIENCES CORPORATION ANNUAL REPORT ON FORM 10‑K YEAR ENDED DECEMBER 31, 2022 TABLE OF CONTENTS Page No. Part I Item 1. Business 4 Item 1A. Risk Factors 19Analyst Report: Exact Sciences Corporation Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and ... Feb 23, 2023 · MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 ... 15-Nov-2023 ... The projected fair value for Exact Sciences is US$109 based on 2 Stage Free Cash Flow to Equity · Exact Sciences' US$63.46 share price signals ...Transcript : Exact Sciences Corporation Presents at Baird's Global Healthcare Conference 2023, Sep-12-2023 10:50 AM Sep. 12: CI Exact Sciences Corporation acquired Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A) for approximately $54.2 million. Sep. 11: CIIn the past year, this Zacks Rank #2 (Buy) stock has surged 88.5% against a 9.7% decline of the industry and a 18% rise of the S&P 500 composite. The renowned global medical device company has a ...The average of price targets set by Wall Street analysts indicates a potential upside of 51.7% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. Find the latest Exact Sciences Corporation (EXAS ...

Shares of Exact Sciences Corporation ( EXAS -0.26%) were down 11.3% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare company's ...

How to Buy EXAS stock: 1. Open A Brokerage Account. To start investing, you will need a brokerage account. There are many brokerage companies on the market. However, they differ in the broker's commission, the number of markets available for investing, the complexity of the platform, and the ease of opening an account.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended ...Stocks Exact Sciences Corp Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns...EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings …Analyst Recommendations on Exact Sciences Corporation. Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating. Nov. 03. MT. BofA …Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests.Exact Sciences Corp. (EXAS) will release its next earnings report on Feb 20, 2024. In the last quarter Exact Sciences Corp. reported -$0.471 EPS in relation to $0 expected by the market. ... Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including ...Globally, the cancer diagnostics market was worth $172.3 billion in 2022, according to analysts from Grand View Research. And by 2030, they project that will rise to $293.5 billion, averaging a ...Sentiment. Exact Sciences (EXAS) has an AI Score of /10 (Buy) because its overall probability of beating the market (S&P 500) in the next 3 months (43.63%) is +42.63% vs. the average probability (%) of US stocks analyzed by our Artificial Intelligence. The AI-powered overall analysis of Exact Sciences (EXAS) is based on the fundamental ...5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024. We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT. Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.

Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ...Nov 22, 2023 · Buy candidate since Nov 17, 2023 Loss -1.39% PDF. The EXACT Sciences Corporation stock price gained 0.368% on the last trading day (Wednesday, 22nd Nov 2023), rising from $65.14 to $65.38. During the last trading day the stock fluctuated 3.02% from a day low at $64.84 to a day high of $66.80. The price has been going up and down for this period ... Corporate Impact and Community Relations. Our Collaborations. Contact Us. Newsroom. News & Stories. ... Stock Information. ... CANCER IS DETECTED TOO LATE. Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful ...Instagram:https://instagram. best broker for option tradingpublic storage reitbest lithium ion battery stockshow to purchase a building with no money Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more. forex mobile appmoomoo commission fee Nov 30, 2023 · 30,994.67. -0.26%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.OQ) real-time stock quotes, news, price and financial information from Reuters to ... Third-quarter 2023 financial results. For the three-month period ended September 30, 2023, as compared to the same period of 2022 (where applicable): • Total revenue was $628.3 million, an increase of 20 percent. • Core revenue was $624.8 million, an increase of 23 percent. • Screening revenue was $472.0 million, an increase of 31 percent. gle 63 amg s Exact Sciences Corporation. 01 Aug, 2023, 16:05 ET. Reports record results, generates positive free cash flow, raises full-year guidance. Second-quarter 2023 highlights. Total second quarter ...Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful treatment. Our TestsAll. Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption. Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.